Medical Devices · Irvine, California, United States
$11.72
+0.51% (+$0.06)2026-05-26
EPS$-0.93
Market Cap$508.0M
Price Performance
Historical data including institutional events
Loading price data...
Company Profile
S
Sean Saint
CEO & Executive Director
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.
It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system.
The company was incorporated in 2015 and is headquartered in Irvine, California.
Founded
2015
Loading company sections...
⚡
Core Efficiency
D/E Ratio?
-0.30
📊
Profitability Ratios
Current Ratio?
6.29
Loading comparison...
Earnings Calendar
Filing history and next expected filing date
Mar 28, 2025
10-K/AQ4 202427d after period end
Data Freshness
Financial Data
1mo ago
Latest filing: 2026-02-24
SEC Metadata
2mo ago
Latest filing: 2026-02-24
Recent Insider Trades
Hopman Mark — Sale 353 shares at $11.57 on 2026-03-04
Hopman Mark — Sale 834 shares at $12.36 on 2026-03-02
Mensinger Mike — Sale 1,064 shares at $12.36 on 2026-03-02
Feider Stephen — Sale 1,428 shares at $12.36 on 2026-03-02